MARKETS / NYSE / RDY

NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

DR Reddys Laboratories Ltd. RDY

10 fiscal years on record · INR · FY2024 reported · SEC filings only

Revenue

INR 325.5B

▲ 16.6% YoY

Net income

INR 56.5B

▲ 1.5% YoY

Free cash flow

INR 18.9B

▼ 34.8% YoY

In brief

What this company does

Dr. Reddy's develops, manufactures and markets generic medicines, with a focus on credible brands, first-to-market launches and differentiated offerings. Its reportable operating segments are Global Generics, Pharmaceutical Services and Active Ingredients, and Others. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products, marketed either under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. Its Pharmaceutical Services and Active Ingredients segment primarily manufactures and markets active pharmaceutical ingredients and intermediates, known as API, which are the principal ingredients for finished pharmaceutical products. It sells its products primarily through clearing and forwarding agents to approximately 6,500 wholesalers who decide which brands to buy based on demand.

Written from the business description in DR. REDDY’S LABORATORIES LIMITED's annual report to the U.S. Securities and Exchange Commission, filed 29 May 2026. Every sentence was checked against that document before publication.

Growth

INR 325.5B

Revenue, FY2024 · full 10-year series below

Revenue INR B Net income INR B

FY2024 · Revenue 325.5 · Net income 56.5

Compound annual growth

Revenue

+14.9%

+13.3%

Returned to shareholders

+24.8%

+12.9%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +13.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

18 cents

of every revenue dollar became profit

Operating margin Net margin

FY2024 · Operating 22.1% · Net 17.6%

ROE

FY2024 · ROE 18.4%

Gross margin58.5%

Operating margin22.1%

Net margin17.6%

Return on assets13.0%

EBITDA—

Each INR of equity produced 18 cents of profit this year.

Cash & shareholders

INR 8.1B

returned in FY2024 · dividends + net buybacks

Free cash flow INR B

FY2024 · FCF 18.9

Net buybacks INR B Dividends INR B

FY2024 · Dividends 6.7 · Net buybacks 1.4

Dividends paidINR 6.7B

Net buybacksINR 1.4B

Share of profit14.2%

Consecutive raises—

INR 6.7B in dividends and INR 1.4B in buybacks — 14% of the year's profit went back to shareholders.

Total assetsINR 493.0B

EquityINR 333.4B

CashINR 14.7B

Gross debtINR 8.7B

Net debtINR -5.9B

Current ratio1.92×

The company holds more cash than debt.

The 10-year record

10 fiscal years

Every figure from documents filed with the SEC · INR

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue INR B	325.5	279.2	245.9	214.4	189.7	174.6	153.9	142.0	140.8	154.7
Operating income INR B	71.8	67.7	57.1	29.5	24.3	16.0	20.9	11.9	13.5	29.6
EBITDA INR B	·	·	·	·	·	·	·	23.6	24.8	39.9
Income tax INR B	19.5	16.2	15.3	8.7	9.2	−1.5	3.6	4.5	2.6	7.1
Net income INR B	56.5	55.7	45.1	23.6	17.2	19.5	18.8	9.8	12.0	20.0
Free cash flow INR B	18.9	29.0	47.6	13.4	26.0	25.0	21.7	8.7	9.2	29.2
EPS, diluted INR	67.78	66.80	54.17	141.69	103.65	117.40	113.09	59.00	72.09	116.98
Dividend / sh INR	40.00	40.00	30.00	25.00	25.00	20.00	20.00	20.00	20.00	20.00
Payout %	12	12	11	18	24	20	21	41	28	21
ROE %	18.4	19.8	·	·	·	·	·	·	·	·
Shares out B	0.83	0.83	0.83	0.17	0.17	0.17	0.17	0.17	0.17	0.17

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 48 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 47 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onNYSE

Incorporated inoutside the United States — SEC code K7

Fiscal year endsMarch 31

Data on record since2015